Dr. Schmid on the Design and Findings of the KEYNOTE-173 Trial in TNBC
December 14th 2018
Peter Schmid, MD, PhD, lead at the Centre for Experimental Cancer Medicine, Barts Cancer Institute, discusses the phase Ib study of pembrolizumab (Keytruda) in combination with chemotherapy for patients with triple negative breast cancer (TNBC).